A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma

Inclusion Criteria * Patient must have a histologically confirmed diagnosis of Kaposi's sarcoma. * Positive antibody to HIV confirmed by ELISA or Western blot on the same serum. Exclusion Criteria * Active drug or alcohol abuse. Co-existing Condition: Patients with the following complications are excluded: * Active opportunistic infections requiring ongoing therapy. * Pneumocystis carinii pneumonia (PCP) unless recovered must be off therapy within 90 days prior to study. * Clinically significant cardiac disease, including a history of myocardial infarction or arrhythmia. * Concurrent neoplasms other than basal cell carcinoma of skin. * Known sensitivity to polymycin or neomycin. Patients with the following complications are excluded: * Active opportunistic infections requiring ongoing therapy. * Pneumocystis carinii pneumonia (PCP) unless recovered must be off therapy within 90 days prior to study. * Clinically significant cardiac disease, including a history of myocardial infarction or arrhythmia. * Concurrent neoplasms other than basal cell carcinoma of skin. * Known sensitivity to polymycin or neomycin. Prior Medication: Excluded: * Any prior zidovudine (AZT) or interferon alpha protocol participation. * Excluded within 30 days of study entry: * Immunomodulating agents. * Other drugs that can cause neutropenia or significant nephrotoxicity, or systemic anti-infectives. * Excluded within 90 days of study entry: * Antiretroviral agents. * Treatment of Pneumocystis…